Cost-effectiveness analysis of the combination of enfortumab vedotin and pembrolizumab in first-line treatment of previously untreated advanced urothelial carcinoma

Authors
Category Primary study
JournalChin. J. New Drugs
Year 2026
This article has no abstract
Epistemonikos ID: 3599090e6b7e54852e76edca6ff64040bd12bc54
First added on: Oct 17, 2026